Ecolab Inc. ECL recently announced that its AdvaCare Disinfectant has received the first approval given by the U.S. Environmental Protection Agency (EPA). This crucial approval is for a laundry disinfectant and oxidizer emerging viral pathogen claim that is effective against SARS-CoV-2 — the virus causing COVID-19. The company’s Global Industrial segment is likely to get a boost following this approval.
AdvaCare Disinfectant is an EPA-registered laundry disinfectant. Notably, the concentrated formulation is allowed for utilization in commercial and industrial laundry operations.
Significance of the Approval
This disinfectant provides the highest level of cleanliness for reusable textiles with the emerging viral pathogen claim for SARS-CoV-2 offering additional assurance to commercial laundries and customers they cater to. In fact, this is the first laundry antimicrobial additive that has an emerging viral pathogen claim, which can be directly dosed into the wash procedure in both tunnel washers and large conventional commercial laundry machines.
Ecolab is committed toward building innovative disinfection technology, thereby enabling the company to set a new standard in the commercial laundry industry. With this approval, the company’s innovative technology is likely to protect people during the pandemic.
In February, Ecolab — a global leader in commercial laundry solutions — launched PolyVantage, which is a revolutionary laundry detergent. PolyVantage’s proprietary blend is the first-of-its-kind solution in the commercial laundry industry developed to tackle tough food oil stains effectively and deliver unparalleled linen quality. Its unique detergent blend, which performs at low temperatures with low alkalinity levels, lowers reprocessing costs and boosts customer satisfaction.
This Zacks Rank #3 (Hold) stock has gained 15% in a year’s time compared with the industry’s growth of 46%.
Some better-ranked stocks from the broader medical space include Aphria Inc. APHA, HMS Holdings Corp. HMSY and West Pharmaceutical Services, Inc. WST. While Aphria and HMS Holdings carry a Zacks Rank #2 (Buy), West Pharmaceutical sports a Zacks Rank #1 (Strong Buy).You can see the complete list of today’s Zacks #1 Rank stocks here.
Aphria has an estimated long-term earnings growth rate of 24.6%.
HMS Holdings has an estimated long-term earnings growth rate of 11%.
West Pharmaceutical has a projected long-term earnings growth rate of 9.2%.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Ecolab Inc. (ECL) : Free Stock Analysis Report
HMS Holdings Corp (HMSY) : Free Stock Analysis Report
West Pharmaceutical Services, Inc. (WST) : Free Stock Analysis Report
Aphria Inc. (APHA) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research